- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 333/34 - Atomes de soufre
Détention brevets de la classe C07D 333/34
Brevets de cette classe: 301
Historique des publications depuis 10 ans
|
22
|
19
|
11
|
17
|
18
|
13
|
16
|
17
|
12
|
13
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novartis AG | 10626 |
17 |
| Allergan, Inc. | 2315 |
12 |
| The Johns Hopkins University | 5752 |
10 |
| Cardioxyl Pharmaceuticals, Inc. | 47 |
9 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 168 |
7 |
| The University of Queensland | 665 |
7 |
| Oxford Drug Design Limited | 10 |
7 |
| Wyeth | 321 |
6 |
| The Institute of Cancer Research: Royal Cancer Hospital | 183 |
5 |
| Baylor College of Medicine | 972 |
4 |
| Kancera AB | 30 |
4 |
| Tokyo Ohka Kogyo Co., Ltd. | 1550 |
4 |
| IFM Tre, Inc. | 5 |
4 |
| Reata Pharmaceuticals Holdings, LLC | 49 |
4 |
| Sumitomo Chemical Company, Limited | 9110 |
3 |
| The Regents of the University of Michigan | 4776 |
3 |
| Metabrain Research | 11 |
3 |
| Pharmaxis Ltd | 36 |
3 |
| Sumitomo Seika Chemicals Co., Ltd. | 1054 |
3 |
| Tetraphase Pharmaceuticals, Inc. | 51 |
3 |
| Autres propriétaires | 183 |